Polymorphic forms of dasatinib
The present invention provides for the dasatinib- thymine co-crystal and dasatinib-adenine co-crystal. The present invention further provides dasatinib-butanediol solvate. The present invention further provides for crystalline dasatinib-(±) - 1, 2-Butane diol, crystalline dasatinib (R)-1, 2-Butanedi...
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | English |
Published |
05.03.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention provides for the dasatinib- thymine co-crystal and dasatinib-adenine co-crystal. The present invention further provides dasatinib-butanediol solvate. The present invention further provides for crystalline dasatinib-(±) - 1, 2-Butane diol, crystalline dasatinib (R)-1, 2-Butanediol, crystalline dasatinib (S)-1, 2-Butanediol and crystalline dasatinib (±)-2, 3-Butanediol and processes for preparation thereof. The present invention also provides for a process for preparation of amorphous dasatinib using dasatinib- butanediol solvate. The present invention further provides for the preparation of anhydrous dasatinib. The present invention also provides for a process for preparation of dasatinib monohydrate from anhydrous dasatinib |
---|---|
Bibliography: | Application Number: AU20180297710 |